{"id":"anticoagulant-treatment-rivaroxaban","safety":{"commonSideEffects":[{"rate":"1-5","effect":"Bleeding"},{"rate":"3-10","effect":"Dyspepsia"},{"rate":"1-3","effect":"Abdominal pain"},{"rate":"1-3","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL198362","moleculeType":"Small molecule","molecularWeight":"435.89"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rivaroxaban selectively inhibits Factor Xa, a key enzyme in the intrinsic and extrinsic coagulation pathways. By blocking Factor Xa, it prevents the conversion of prothrombin to thrombin, thereby reducing thrombin generation and inhibiting clot formation. This oral anticoagulant is used to prevent and treat thromboembolism in various clinical settings.","oneSentence":"Rivaroxaban is a direct Factor Xa inhibitor that blocks the coagulation cascade to prevent blood clot formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:01:52.593Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"},{"name":"Deep vein thrombosis (DVT) prevention and treatment"},{"name":"Pulmonary embolism (PE) prevention and treatment"},{"name":"Acute coronary syndrome"}]},"trialDetails":[{"nctId":"NCT03568890","phase":"PHASE4","title":"Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec","startDate":"2018-09-01","conditions":"Left Atrial Appendage Closure, Thrombosis, Stroke","enrollment":510},{"nctId":"NCT07497893","phase":"NA","title":"FENOX Trial (Comparative Effectiveness of Fexuprazan Co-therapy in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants)","status":"NOT_YET_RECRUITING","sponsor":"Ewha Womans University Mokdong Hospital","startDate":"2026-12-01","conditions":"Atrial Fibrillation (AF), Upper Gastrointestinal Bleeding (UGIB), Gastrointestinal Hemorrhage (Clinically Important, Upper)","enrollment":1000},{"nctId":"NCT05387954","phase":"PHASE3","title":"PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-07-07","conditions":"Cryptogenic Ischemic Stroke, Patent Foramen Ovale","enrollment":792},{"nctId":"NCT05900388","phase":"","title":"A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE)","status":"NOT_YET_RECRUITING","sponsor":"Bayer","startDate":"2026-09-01","conditions":"Venous Thromboembolism, Children Under 2 Years","enrollment":850},{"nctId":"NCT07456085","phase":"PHASE3","title":"Rivaroxaban vs Warfarin in Patients With Mechanical Heart Valves","status":"ENROLLING_BY_INVITATION","sponsor":"Rawalpindi Institute of Cardiology","startDate":"2025-11-13","conditions":"Valvular Heart Disease Patients","enrollment":60},{"nctId":"NCT04618913","phase":"","title":"Anticoagulation in Patients With Venous Thromboembolism and Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2020-12-14","conditions":"Neoplasms, Embolism","enrollment":1},{"nctId":"NCT05038228","phase":"","title":"High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2022-08-01","conditions":"Atrial Fibrillation","enrollment":1},{"nctId":"NCT06901466","phase":"PHASE4","title":"STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients With an Indication for Oral Anticoagulant","status":"RECRUITING","sponsor":"Chinese Academy of Medical Sciences, Fuwai Hospital","startDate":"2025-06-13","conditions":"Mitral Regurgitation","enrollment":880},{"nctId":"NCT06055920","phase":"NA","title":"The PEERLESS II Study","status":"RECRUITING","sponsor":"Inari Medical","startDate":"2023-11-17","conditions":"Pulmonary Embolism","enrollment":1200},{"nctId":"NCT04874428","phase":"PHASE1","title":"Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2021-05-19","conditions":"Liver Cirrhosis","enrollment":24},{"nctId":"NCT07242326","phase":"","title":"SNAP AF-52: Dose Appropriateness and Adherence to Oral Anticoagulation in Adults ≥65 With Atrial Fibrillation in Primary Care (Ordu, Türkiye)","status":"ENROLLING_BY_INVITATION","sponsor":"Kotyora Family Medicine Health Management and Education Association","startDate":"2025-12-15","conditions":"Medication Adherence, Atrial Fibrillation (AF), Direct Oral Anticoagulants (DOACs)","enrollment":1000},{"nctId":"NCT05825573","phase":"PHASE3","title":"Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2023-05-15","conditions":"Intracardiac Thrombus, STEMI, Heart Failure","enrollment":340},{"nctId":"NCT05701917","phase":"NA","title":"DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis","status":"RECRUITING","sponsor":"Inari Medical","startDate":"2023-01-06","conditions":"Venous Thromboembolism, Deep Venous Thrombosis, Post-Thrombotic Syndrome","enrollment":300},{"nctId":"NCT07358416","phase":"","title":"Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Petrovsky National Research Centre of Surgery","startDate":"2025-05-01","conditions":"Thrombosis, Bleeding, Cerebral Hypoxia During and/or Resulting From A Procedure","enrollment":500},{"nctId":"NCT04045665","phase":"PHASE3","title":"Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2019-12-13","conditions":"Atrial Fibrillation, Stroke, Bleeding","enrollment":3200},{"nctId":"NCT07352358","phase":"PHASE4","title":"Randomized Trial of Anticoagulation Plus Batroxobin for Acute Cerebral Venous Thrombosis","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2026-01-30","conditions":"Cerebral Venous Thrombosis","enrollment":72},{"nctId":"NCT06370273","phase":"PHASE3","title":"Thromboprophylaxis in Lower Limb Immobilisation","status":"RECRUITING","sponsor":"Queen Mary University of London","startDate":"2024-11-12","conditions":"Thrombosis, Injury Leg","enrollment":10044},{"nctId":"NCT05838664","phase":"","title":"A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-07-07","conditions":"Atrial Fibrillation","enrollment":2140403},{"nctId":"NCT06195540","phase":"PHASE3","title":"RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing","status":"RECRUITING","sponsor":"University Hospital, Angers","startDate":"2024-07-19","conditions":"Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism","enrollment":1424},{"nctId":"NCT02810704","phase":"PHASE4","title":"Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2016-12","conditions":"Pulmonary Embolism, Venous Thrombosis","enrollment":18883},{"nctId":"NCT04755283","phase":"PHASE2","title":"Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Anthos Therapeutics, Inc.","startDate":"2021-02-02","conditions":"Atrial Fibrillation (AF), Stroke","enrollment":1287},{"nctId":"NCT07202897","phase":"PHASE3","title":"LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.","status":"NOT_YET_RECRUITING","sponsor":"Rennes University Hospital","startDate":"2025-10-01","conditions":"Hypertrophic Cardiomyopathy (HCM)","enrollment":532},{"nctId":"NCT04284839","phase":"PHASE3","title":"The Direct Oral Anticoagulation Versus Vitamin K Antagonist After Cardiac Surgery Trial","status":"RECRUITING","sponsor":"Population Health Research Institute","startDate":"2021-07-18","conditions":"Bleeding Post Cardiac Surgery, Indication for Anticoagulation","enrollment":3500},{"nctId":"NCT04694248","phase":"NA","title":"Anticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2021-11-03","conditions":"Deep Vein Thrombosis, Iliac Vein Thrombosis, Iliac Vein Obstruction","enrollment":172},{"nctId":"NCT07173075","phase":"NA","title":"Evaluation of the Relationship Between Muscle Mass Measured by Bioelectrical Impedance Analysis and the Risk of Hemorrhagic Events Under Direct Oral Anticoagulants in the Elderly","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2025-10","conditions":"Direct Oral Anticoagulant, Hemmorhage, Elderly","enrollment":110},{"nctId":"NCT06581965","phase":"PHASE4","title":"inDividual, Targeted thrombosIS Prophylaxis Versus the Standard 'One Size Fits All' Approach in Patients Undergoing Total hIp or Total kNee replaCemenT","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2024-11-11","conditions":"Venous Thromboembolism, Venous Thromboses, Pulmonary Embolism","enrollment":10078},{"nctId":"NCT07083609","phase":"","title":"Treatment Outcomes of Direct Oral Anticoagulants in Cerebral Venous Thrombosis in Vietnam","status":"RECRUITING","sponsor":"Hieu Trung Dinh","startDate":"2025-07-11","conditions":"Cerebral Venous Thrombosis","enrollment":69},{"nctId":"NCT05990894","phase":"","title":"Steroid for Treatment of Acute/Subacute Severe Cerebral Venous Thrombosis.","status":"COMPLETED","sponsor":"Xuanwu Hospital, Beijing","startDate":"2020-07-01","conditions":"Cerebral Venous Thrombosis","enrollment":170},{"nctId":"NCT03778502","phase":"","title":"DOAC in Unusual Site Venous Thrombosis","status":"COMPLETED","sponsor":"University of Malta","startDate":"2019-10-01","conditions":"Splanchnic Vein Thrombosis, Cerebral Vein Thrombosis, Ovarian Vein Thrombosis","enrollment":358},{"nctId":"NCT05643651","phase":"PHASE4","title":"Rivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2025-06-01","conditions":"Kawasaki Disease, Coronary Artery Aneurysm","enrollment":100},{"nctId":"NCT07011095","phase":"EARLY_PHASE1","title":"DOAC or VKA in Patients With AF and Stroke While on DOAC - a Pilot Trial","status":"NOT_YET_RECRUITING","sponsor":"Population Health Research Institute","startDate":"2025-09-03","conditions":"Atrial Fibrillation (AF), Stroke (in Patients With Atrial Fibrillation)","enrollment":100},{"nctId":"NCT06993636","phase":"","title":"Pharmacometrics Analysis of Rivaroxaban in Chinese Children Aged Over 2 Years","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2023-01-01","conditions":"Kawasaki Disease, Coronary Artery Aneurysm, Rivaroxaban","enrollment":60},{"nctId":"NCT06983795","phase":"","title":"Pioneering Advancements in Cardiocerebrovascular Interactions in the Asia pacFIC - Patent Foramen Ovale Study","status":"NOT_YET_RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2025-07","conditions":"Ischemic Stroke, Patent Foramen Ovale","enrollment":1000},{"nctId":"NCT04700826","phase":"PHASE4","title":"Preventing Stroke, Premature Death and Cognitive Decline in a Broader Community of Patients With Atrial Fibrillation","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2021-06-01","conditions":"Atrial Fibrillation","enrollment":3000},{"nctId":"NCT05735639","phase":"PHASE4","title":"THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)","status":"RECRUITING","sponsor":"Imperial College London","startDate":"2024-01-22","conditions":"Venous Thromboembolism, Varicose Veins","enrollment":6660},{"nctId":"NCT04394234","phase":"","title":"A Study of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-05-15","conditions":"Uterine Hemorrhage","enrollment":961985},{"nctId":"NCT06925698","phase":"PHASE3","title":"Immunosuppressive Therapy Alone Versus Plus Oral Anticoagulation in the Treatment of VT Associated With Behcet's Disease","status":"NOT_YET_RECRUITING","sponsor":"Marmara University","startDate":"2025-04-30","conditions":"Behcet Disease, Behcet Disease and Vascular Involvement, Deep Venous Thromboses","enrollment":110},{"nctId":"NCT06449469","phase":"NA","title":"The Nordic Aortic Valve Intervention Trial 4 (NOTION-4)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2021-05-01","conditions":"Aortic Valve Stenosis, Cardiovascular Diseases, Heart Diseases","enrollment":352},{"nctId":"NCT06322953","phase":"PHASE3","title":"Timing to Restart Direct Oral Anticoagulants After Traumatic Intracranial Haemorrhage","status":"RECRUITING","sponsor":"Walton Centre NHS Foundation Trust","startDate":"2025-03-10","conditions":"Traumatic Intracranial Haemorrhage","enrollment":1084},{"nctId":"NCT06571149","phase":"PHASE4","title":"Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2025-03-14","conditions":"Ischemic Stroke","enrollment":906},{"nctId":"NCT04724460","phase":"PHASE4","title":"Optimal Duration of Anticoagulation Therapy for Low-risk Pulmonary Embolism Patients With Cancer","status":"COMPLETED","sponsor":"Takeshi Morimoto","startDate":"2021-02-18","conditions":"Venous Thrombosis, Neoplasms, Anticoagulants","enrollment":179},{"nctId":"NCT06862726","phase":"PHASE4","title":"Apixaban Versus Rivaroxaban in Non Valvular Atrial Fibrillation","status":"ENROLLING_BY_INVITATION","sponsor":"Les Laboratoires des Médicaments Stériles","startDate":"2024-12-01","conditions":"Non Valvular Atrial Fibrillation","enrollment":120},{"nctId":"NCT05068414","phase":"","title":"Assessment of the Incidence of Hemorrhagic and Ischemic Events in Post-angioplasty in Anticoagulated Coronary Patients with Atrial Fibrillation","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2021-04-12","conditions":"Atrial Fibrillation, Acute Coronary Syndrome, Thrombosis","enrollment":122},{"nctId":"NCT04234698","phase":"","title":"Patient Characteristics, Treatment Patterns And Incidence Of Events (Discontinuation, Persistence, Key Primary Clinical Outcomes) In NVAF Patients Initiating OAC Therapy In Colombia","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-03-22","conditions":"Atrial Fibrillation","enrollment":2076},{"nctId":"NCT06780462","phase":"PHASE3","title":"Randomized Controlled Multicenter Study Comparing Steroid Therapy Plus Anticoagulants to Steroid Therapy Alone in Deep Venous Thrombosis of Behçet's Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-01-15","conditions":"Behcet Syndrome","enrollment":134},{"nctId":"NCT03996772","phase":"PHASE3","title":"PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2019-06-03","conditions":"Atrial Fibrillation, Intracerebral Hemorrhage","enrollment":319},{"nctId":"NCT03062319","phase":"PHASE4","title":"Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis","status":"TERMINATED","sponsor":"National Hospital Organization Osaka National Hospital","startDate":"2017-04-06","conditions":"Ischemic Stroke, Atrial Fibrillation, Atherothrombosis","enrollment":321},{"nctId":"NCT01924065","phase":"PHASE3","title":"Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation","status":"COMPLETED","sponsor":"Suleyman Demirel University","startDate":"2013-08","conditions":"Atrial Fibrillation, Cardioversion, Cerebrovascular Stroke","enrollment":112},{"nctId":"NCT04979780","phase":"","title":"Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-07-20","conditions":"Treatment of Venous Thromboembolism in Cancer Patients, Prophylaxis of Recurrent Venous Thromboembolism in Cancer Patients","enrollment":3708},{"nctId":"NCT06615596","phase":"EARLY_PHASE1","title":"Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation","status":"NOT_YET_RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2025-01","conditions":"Atrial Fibrillation (AF)","enrollment":3160},{"nctId":"NCT06284343","phase":"","title":"The Gynecological Cancer Associated Thrombosis (GynCAT) Study","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2024-04-15","conditions":"Cancer-associated Thrombosis, Venous Thromboembolism, Gynecologic Cancer","enrollment":1800},{"nctId":"NCT04477837","phase":"","title":"Prospective Comparison of Incidence of Heavy Menstrual Bleeding in Women Treated With Direct Oral Anticoagulants","status":"COMPLETED","sponsor":"Cardioangiologisches Centrum Bethanien","startDate":"2020-10-15","conditions":"Heavy Menstrual Bleeding","enrollment":84},{"nctId":"NCT04970381","phase":"NA","title":"An Exploratory stuDy of effectIveneSs and Safety of rivarOxaban in Patients With Left VEntricular Thrombus (R-DISSOLVE)","status":"COMPLETED","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2020-09-27","conditions":"Ventricular Mural Thrombosis","enrollment":75},{"nctId":"NCT04249401","phase":"","title":"Study to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem)","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-03-01","conditions":"Atrial Fibrillation","enrollment":134897},{"nctId":"NCT02735902","phase":"PHASE4","title":"Anticoagulation Alone Versus Anticoagulation and Aspirin Following Transcatheter Aortic Valve Interventions (1:1)","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2017-06-01","conditions":"Transcatheter Aortic Valve Replacement","enrollment":170},{"nctId":"NCT06232551","phase":"NA","title":"Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism","status":"RECRUITING","sponsor":"Scott C. Woller, MD","startDate":"2024-06-01","conditions":"Venous Thromboembolic Disease, Pulmonary Embolism and Thrombosis, Deep Vein Thrombosis","enrollment":152000},{"nctId":"NCT06486792","phase":"PHASE4","title":"Stroke Prevention In Ischemic Stroke With Covert Atrial Fibrillation","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-09-01","conditions":"Stroke, Ischemic Stroke, Cerebral Infarction","enrollment":1148},{"nctId":"NCT06476301","phase":"PHASE4","title":"Efficacy and Safety of Rivaroxaban in the Early Postoperative Period for Patients With Bioprosthetic Valves","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","startDate":"2024-08-01","conditions":"Anticoagulation","enrollment":250},{"nctId":"NCT04847752","phase":"","title":"Study of Predictive Factors Related to Prognosis of Patients With Ischemic Stroke Due to Large-artery Atherosclerosis","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2021-03-01","conditions":"Ischemic Stroke, Large-Artery Atherosclerosis (Embolus/Thrombosis)","enrollment":1000},{"nctId":"NCT06021808","phase":"NA","title":"LAA Clipping Versus NOACs to Prevent Stroke in Non-paroxysmal Atrial Fibrillation.","status":"RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2024-04-02","conditions":"Non-paroxysmal Atrial Fibrillation","enrollment":290},{"nctId":"NCT05472766","phase":"NA","title":"Anticoagulation Therapy Timing in Atrial Fibrillation After Acute and Chronic Subdural Hematoma","status":"TERMINATED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2022-11-24","conditions":"Subdural Hematoma, Atrial Fibrillation","enrollment":1},{"nctId":"NCT06401616","phase":"PHASE4","title":"Can Patients With Atrial Fibrillation Safely Discontinue Anticoagulant Therapy After Cardiac Surgery? (ATLAAC)","status":"RECRUITING","sponsor":"Odense University Hospital","startDate":"2024-05-21","conditions":"Atrial Fibrillation, Left Atrial Appendage Absent, Anticoagulant Adverse Reaction","enrollment":1220},{"nctId":"NCT03759938","phase":"NA","title":"OPTIMAS: OPtimal TIMing of Anticoagulation After Acute Ischaemic Stroke : a Randomised Controlled Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University College, London","startDate":"2019-06-18","conditions":"Stroke, Acute, Atrial Fibrillation","enrollment":3648},{"nctId":"NCT06375070","phase":"","title":"Anticoagulants for PFO Patients","status":"COMPLETED","sponsor":"Xuanwu Hospital, Beijing","startDate":"2016-08","conditions":"Patent Foramen Ovale","enrollment":277},{"nctId":"NCT06057467","phase":"NA","title":"Early Versus Late Initiation of Anticoagulation in Mild-to-moderate AIS Patients With NVAF","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-09-15","conditions":"Acute Ischemic Stroke, Atrial Fibrillation","enrollment":2351},{"nctId":"NCT06058130","phase":"NA","title":"Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-09-29","conditions":"Acute Ischemic Stroke, Atrial Fibrillation, Stenosis, Carotid","enrollment":2171},{"nctId":"NCT01613443","phase":"","title":"Ex-vivo Effect of New Oral Anticoagulants on Point-of-care Devices","status":"COMPLETED","sponsor":"Cardioangiologisches Centrum Bethanien","startDate":"2012-06","conditions":"Effect of NOAC on POCT","enrollment":100},{"nctId":"NCT04042155","phase":"","title":"Real-life Clinical Outcomes of Direct Oral Anticoagulants (MACACOD)","status":"UNKNOWN","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2019-07-29","conditions":"Atrial Fibrillation, Recurrent Venous Thromboembolism","enrollment":1600},{"nctId":"NCT04262492","phase":"","title":"International Registry of Thrombotic APS Patients Treated With Direct Oral Anticoagulants","status":"RECRUITING","sponsor":"Stéphane Zuily","startDate":"2020-10-21","conditions":"Antiphospholipid Syndrome, Thrombosis, Anticoagulants Causing Adverse Effects in Therapeutic Use","enrollment":500},{"nctId":"NCT05638867","phase":"PHASE4","title":"NOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI","status":"RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2023-11-25","conditions":"Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome","enrollment":3944},{"nctId":"NCT06187311","phase":"PHASE4","title":"Clinical Trial to Evaluate Efficacy and Safety of Rivaroxaban 15mg and 20mg in Patients With Non-valvular Atrial Fibrillation","status":"RECRUITING","sponsor":"Korea University Anam Hospital","startDate":"2023-01-12","conditions":"Atrial Fibrillation, Anticoagulant Adverse Reaction","enrollment":940},{"nctId":"NCT05723510","phase":"PHASE1","title":"PK and PD Interaction Between Tegoprazan and NOACs After Multiple Oral Dosing in Healthy Volunteers","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2023-03-06","conditions":"Healthy","enrollment":87},{"nctId":"NCT03684564","phase":"PHASE2","title":"RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome","status":"UNKNOWN","sponsor":"University College, London","startDate":"2021-07-09","conditions":"Antiphospholipid Syndrome, Systemic Lupus Erythematosus, Stroke","enrollment":43},{"nctId":"NCT03864406","phase":"PHASE1","title":"Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants (Rivaroxaban, Apixaban) in Health Volunteers","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2019-06-04","conditions":"Healthy Volunteers","enrollment":12},{"nctId":"NCT03772366","phase":"","title":"Genital Haemorrhage in Woman of Childbearing Age Treated for Venous Thromboembolism Disease : Comparison According to Oral Anticoagulant and Impact on Quality of Life","status":"UNKNOWN","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2019-06-01","conditions":"Genital Haemorrhage","enrollment":453},{"nctId":"NCT06145269","phase":"EARLY_PHASE1","title":"Recanalization Rate of Acute DVT","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-12-01","conditions":"Acute DVT of Lower Extremity","enrollment":100},{"nctId":"NCT05143567","phase":"NA","title":"Hemostasis and Inflammation in COVID-19 Patients With Venous and Arterial Thrombotic Complications","status":"COMPLETED","sponsor":"Ryazan State Medical University","startDate":"2021-11-01","conditions":"Venous Thromboembolism, covid19, Thrombosis","enrollment":150},{"nctId":"NCT03455439","phase":"","title":"Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban)","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-03-16","conditions":"Heart Failure","enrollment":552},{"nctId":"NCT02975453","phase":"","title":"Study of Major Cardiovascular Events in Patients With Nonvalvular Atrial Fibrillation Treated With Rivaroxaban","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-12-05","conditions":"Atrial Fibrillation","enrollment":1481},{"nctId":"NCT05022758","phase":"","title":"A Study to Learn Whether There Are Differences in the Kidney's Ability to Work Properly in Korean Patients With Non-valvular Atrial Fibrillation (Irregular and Often Rapid Heartbeat Not Caused by a Heart Valve Problem) Treated With Rivaroxaban as Compared to Those Treated With Warfarin","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-10-06","conditions":"Non-valvular Atrial Fibrillation (NVAF)","enrollment":45000},{"nctId":"NCT06065592","phase":"PHASE1","title":"Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms","status":"UNKNOWN","sponsor":"Lebanese University","startDate":"2019-02-01","conditions":"Cancer, Solid Tumor, Thromboembolism","enrollment":500},{"nctId":"NCT02744092","phase":"NA","title":"Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer","status":"COMPLETED","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2016-12-13","conditions":"Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT)","enrollment":811},{"nctId":"NCT04868214","phase":"","title":"Multi-site Study for Evaluation of Clinical Ranges of Whole Blood Clotting Times of Patients on Anticoagulants and Verification of Measurement Precision of Liquid Quality Controls With the Perosphere Technologies' PoC Coagulometer","status":"UNKNOWN","sponsor":"Sciema UG","startDate":"2021-04-20","conditions":"Coagulation","enrollment":300},{"nctId":"NCT05022563","phase":"","title":"Treatment Patterns and Bleeding Risk of Anticoagulants in Patients With Venous Thromboembolism in Korea","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-08-31","conditions":"Venous Thromboembolism","enrollment":55759},{"nctId":"NCT03148457","phase":"NA","title":"Early Versus Late Initiation of Direct Oral Anticoagulants in Post-ischaemic Stroke Patients With Atrial fibrillatioN (ELAN): an International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2017-11-06","conditions":"Ischaemic Stroke","enrollment":2013},{"nctId":"NCT04679298","phase":"","title":"Point-of-Care Testing of Coagulation in Patients Treated With Direct Oral Anticoagulants Extended","status":"UNKNOWN","sponsor":"University Hospital Tuebingen","startDate":"2021-01-05","conditions":"Anticoagulation With Direct Oral Anticoagulants","enrollment":80},{"nctId":"NCT04297150","phase":"","title":"Predictive Factors for Response to New Oral Anticoagulants in the Treatment of Non-valvular Atrial Fibrillation..","status":"UNKNOWN","sponsor":"Fundación de Investigación Biomédica - Hospital Universitario de La Princesa","startDate":"2020-06-18","conditions":"Atrial Fibrillation","enrollment":700},{"nctId":"NCT03764241","phase":"PHASE3","title":"Treatment of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2020-02-01","conditions":"ST Segment Elevation Myocardial Infarction, Left Ventricular Thrombus","enrollment":280},{"nctId":"NCT05546957","phase":"NA","title":"Assess Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban in Healthy Adult Participants","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-01-05","conditions":"Healthy Volunteer","enrollment":60},{"nctId":"NCT03977363","phase":"","title":"The Portuguese Survey on Anticoagulated Patients Register (START-Portugal-Register)","status":"TERMINATED","sponsor":"CHAD","startDate":"2020-01-27","conditions":"Atrial Fibrillation, Venous Thromboembolism, Heart Valve Diseases or Prosthesis","enrollment":25},{"nctId":"NCT04006288","phase":"PHASE4","title":"Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease","status":"COMPLETED","sponsor":"University of Florida","startDate":"2019-09-06","conditions":"Coronary Artery Disease","enrollment":90},{"nctId":"NCT04808934","phase":"","title":"NOAC Portuguese Real World Study","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2020-06-01","conditions":"Stroke, Systemic Embolism, Major Bleeding","enrollment":""},{"nctId":"NCT05487950","phase":"PHASE4","title":"Rivaroxaban Versus Standard of Care for Patients With Excessive Atrial Ectopy or Short Atrial Runs and High Embolism Risk","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-04-05","conditions":"Excessive Supraventricular Ectopies or Short Atrial Runs (ESVEA)","enrollment":550},{"nctId":"NCT04569279","phase":"PHASE3","title":"Rivaroxaban vs. Warfarin in CVT Treatment","status":"COMPLETED","sponsor":"Damascus University","startDate":"2017-09-01","conditions":"Cerebral Vein Thrombosis","enrollment":71},{"nctId":"NCT02219984","phase":"","title":"START-Register: Survey on Anticoagulated Patients Register","status":"RECRUITING","sponsor":"GUALTIERO PALARETI","startDate":"2011-10","conditions":"Atrial Fibrillation, Venous Thromboembolism, Heart Valve Diseases or Prosthesis","enrollment":15410},{"nctId":"NCT02353585","phase":"","title":"Novel Oral Anticoagulants in Stroke Patients","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2014-12","conditions":"Ischemic Stroke, Intracranial Hemorrhages","enrollment":1050},{"nctId":"NCT01776424","phase":"PHASE3","title":"Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-02-28","conditions":"Prevention & Control","enrollment":27395},{"nctId":"NCT03292666","phase":"","title":"Anticoagulation Length of ThErapy and Risk of New Adverse evenTs In Venous thromboEmbolism Study","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2010-01-01","conditions":"Venous Thromboembolism, Anticoagulants and Bleeding Disorders","enrollment":39603},{"nctId":"NCT02664155","phase":"PHASE3","title":"Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2016-10-19","conditions":"Renal Insufficiency","enrollment":203},{"nctId":"NCT05545475","phase":"","title":"Safety of Anticoagulant Therapy After Tissue Glue for Gastric Varices","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2022-01-01","conditions":"Anticoagulants and Bleeding Disorders, Tissue Adhesion, Gastric Varices Bleeding","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7182,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Anticoagulant treatment Rivaroxaban","genericName":"Anticoagulant treatment Rivaroxaban","companyName":"Rennes University Hospital","companyId":"rennes-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rivaroxaban is a direct Factor Xa inhibitor that blocks the coagulation cascade to prevent blood clot formation. Used for Atrial fibrillation for stroke prevention, Deep vein thrombosis (DVT) prevention and treatment, Pulmonary embolism (PE) prevention and treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}